Huberman LabDr. Thaïs Aliabadi on Huberman Lab: Why PCOS goes undetected
Insulin resistance disrupts the brain-ovary axis to drive PCOS; AMH testing and Tyrer-Cuzick scoring give women early answers on fertility and cancer risk.
CHAPTERS
- 0:00 – 7:00
Women’s Symptoms Are Not ‘In Your Head’
Huberman introduces Dr. Thaïs Aliabadi and frames the episode around PCOS, endometriosis, fertility, menopause, and breast cancer. Aliabadi immediately centers the problem: women’s symptoms are routinely dismissed as anxiety or ‘normal,’ leaving millions with undiagnosed PCOS and endometriosis that silently damage fertility and health.
- •Aliabadi has 30 years in women’s health and sees systemic dismissal of women’s pain and symptoms.
- •PCOS and endometriosis are leading causes of infertility worldwide yet mostly undiagnosed.
- •She treats teens as young as 13–14 with severe endometriosis and near‑depleted ovarian reserve.
- •If all 20‑year‑olds were screened once properly, she believes many fertility clinics could close.
- •Baseline egg count (AMH) and screening for PCOS and endometriosis should be universal in young women.
- 7:00 – 27:00
Why Age-Only Fertility Charts Are Misleading
Huberman asks about typical fertility by age, and Aliabadi explains why standard curves are false for a large fraction of women. PCOS and endometriosis are often unaccounted for, meaning many women in their 20s and 30s already have severely compromised fertility despite reassuring age-based statistics.
- •Women are born with a finite egg pool; quantity and quality decline with age.
- •Endometriosis can obliterate ovarian reserve by age 30—even to zero eggs.
- •PCOS and endometriosis are rarely considered in population fertility “plots.”
- •Real-life fertility must factor in underlying conditions, not just chronological age.
- •Aliabadi urges egg-freezing opportunistically when egg quality is still high and disease is controlled.
- 27:00 – 48:00
PCOS Defined: Criteria, Phenotypes, and Misconceptions
Aliabadi defines PCOS, emphasizing it is common, heterogeneous, and often misdiagnosed—even by specialists. She details the official diagnostic criteria, clarifies that you only need two of three, and explains why normal testosterone labs, absence of cysts, or a lean body do NOT exclude PCOS.
- •PCOS affects ~15% of women in the US, >20% in some regions; Aliabadi believes >70–90% go undiagnosed.
- •Diagnosis requires ≥2 of: (1) clinical or lab hyperandrogenism, (2) ovulatory dysfunction/irregular cycles, (3) PCOS-like ovaries on ultrasound or high AMH.
- •Polycystic ovaries are misnamed; they’re follicles, not true cysts, often appearing as a ‘string of pearls.’
- •Blood testosterone can be normal in PCOS; clinical signs (acne, hair growth/loss) still count.
- •Four phenotypes exist: classic (all criteria), ovulatory PCOS, non-polycystic ovary PCOS, and non-hyperandrogenic PCOS, complicating diagnosis.
- 48:00 – 1:04:00
Teenagers, PCOS, and Careful Labeling
They discuss the challenge of diagnosing PCOS in teens, whose cycles and ovaries naturally look ‘PCOS-like.’ Aliabadi stresses caution about labeling, but also urgency about treating real symptoms early to protect metabolic health and future fertility.
- •In adolescents, ultrasound and AMH are not reliable for PCOS diagnosis because follicles and AMH are naturally high.
- •Teen diagnosis should rely on irregular cycles plus clear androgen symptoms.
- •She often treats without formally labeling teens, using labs and symptom patterns.
- •Many teens with PCOS manifestations are misdirected into eating disorder clinics, where the underlying insulin resistance and hormonal disorder are missed.
- •Early intervention (diet, supplements, medications) can prevent long-term metabolic, reproductive, and psychological damage.
- 1:04:00 – 1:30:00
PCOS Root Causes: Brain–Ovary Axis, Insulin Resistance, and Inflammation
Aliabadi dissects the physiology behind PCOS, explaining the normal hypothalamus–pituitary–ovary loop and how it goes wrong. She then builds out the central pillars of PCOS: disrupted GnRH/LH/FSH balance, insulin resistance, chronic inflammation, genetics, and lifestyle (epigenetics).
- •Normal cycle: pulsatile GnRH → FSH → follicle growth → estradiol peak → LH surge → ovulation → progesterone from corpus luteum.
- •In PCOS, fast GnRH pulses raise LH relative to FSH; LH overstimulates theca cells, producing excess androgens.
- •Androgens stunt follicles, impair ovulation, and drive acne, hair changes, and mood disruption.
- •80% of PCOS patients are insulin resistant; high insulin promotes more ovarian androgens and suppresses SHBG, raising free testosterone.
- •Visceral fat from insulin resistance secretes inflammatory cytokines, which worsen insulin resistance and stimulate more androgens.
- •Genetics ‘load the gun’ for insulin resistance and PCOS, while diet, stress, sleep, and activity ‘pull the trigger.’
- 1:30:00 – 1:50:00
Living With PCOS: Mood, Eating Disorders, and Dismissal
Aliabadi describes the lived experience of PCOS: weight struggles despite extreme dieting, persistent acne, hair loss, irregular cycles, and mood disorders. She explains how these women are repeatedly told to just ‘eat less and exercise more,’ and how stigma, misdiagnosis, and shame drive many into eating disorders and anxiety.
- •PCOS patients often live in thin families and are blamed for weight gain despite doing ‘everything right.’
- •Anxiety, depression, PMDD, and disordered eating are extremely common; Aliabadi estimates 60–70% have some form of disordered eating.
- •Accutane, spironolactone, and endless laser hair removal often treat symptoms without touching root causes.
- •PCOS patients are routinely dismissed as lazy, anxious, or noncompliant, worsening psychological distress.
- •Proper diagnosis, validation, and targeted metabolic/hormonal treatment can dramatically improve mood and self-esteem.
- 1:50:00 – 2:35:00
Treating PCOS: From Supplements to Metformin and GLP‑1s
The focus shifts to treatment. Aliabadi insists that birth control is only a small part of PCOS care and emphasizes first addressing insulin resistance and inflammation via lifestyle and targeted supplements, then medications like metformin and GLP‑1 agonists for appropriate patients.
- •Lifestyle: low‑inflammatory eating, fewer refined carbs, walking after meals, exercise, sleep, and stress control are foundational.
- •Supplements that improve insulin sensitivity and reduce inflammation (e.g., inositol, vitamin D, curcumin, chromium, CoQ10, L‑carnitine, mulberry leaf) can normalize cycles and even restore fertility for some.
- •Aliabadi created the Ovii platform (ovii.com) to help women self-screen for PCOS and start evidence-based supplements.
- •Metformin is commonly underdosed; she typically uses 750–1000 mg twice daily if tolerated, watching for GI side effects.
- •GLP‑1 drugs (e.g., Trulicity, Ozempic/Wegovy equivalents) can rapidly reduce weight, insulin resistance, inflammation, and PCOS symptoms; many women report profound mental relief from constant food noise and cravings.
- •Birth control pills help by inducing SHBG and lowering free testosterone but don’t treat core metabolic drivers; she prefers progestin‑dominant methods in PCOS patients prone to mood issues.
- 2:35:00 – 3:06:00
PCOS and Fertility: Letrozole, Clomid, and When to See a Fertility Clinic
They discuss practical fertility strategies for women with PCOS. Aliabadi outlines how she optimizes hormonal and metabolic health, then uses oral ovulation inducers, and only later escalates to IVF. She notes that many PCOS women are never recognized as such even in fertility clinics.
- •After treating insulin resistance and inflammation, Aliabadi uses letrozole (first-line) or Clomid to induce ovulation in PCOS patients trying to conceive.
- •She usually lets women try 6 months if ≥35 or up to a year if younger and well-optimized before referring to IVF.
- •Despite normal‑appearing cycles, many PCOS women do not truly ovulate; some bleeds are just estrogen withdrawal.
- •High AMH and many follicles in a 40‑year‑old (e.g., 30 follicles, AMH >6) are often a red flag for undiagnosed PCOS, not a guarantee of easy IVF.
- •Women with PCOS are frequently labeled ‘unexplained infertility’ in IVF clinics because clinicians miss the underlying syndrome.
- 3:06:00 – 3:26:00
Endometriosis 101: What It Is and Why It’s Missed
Aliabadi turns to endometriosis, calling it a devastating but grossly underdiagnosed condition. She explains how ectopic endometrial-like tissue bleeds internally every cycle, driving inflammation, adhesions, nerve growth, and pain. Diagnosis is often delayed for nearly a decade, with women dismissed as anxious or oversensitive.
- •Endometriosis is tissue similar to uterine lining growing outside the uterus (ovaries, pelvis, bladder, bowel) that responds to estrogen and bleeds monthly.
- •It is a leading cause of chronic pelvic pain and infertility; Aliabadi believes >20% of women have it.
- •Average diagnostic delay is 9–11 years, with patients seeing 5–10 (or more) doctors before being believed.
- •Classic symptoms: debilitating period pain that disrupts life, deep dyspareunia, bloating, painful bowel movements, and recurrent negative-culture UTIs.
- •Imaging often misses disease; neither ‘normal’ ultrasound nor ‘normal’ MRI reliably excludes endometriosis.
- 3:26:00 – 3:50:00
Mechanisms and Fertility Impact of Endometriosis
The discussion digs into theories of how endometriosis forms, how lesions self-sustain, and how they impair fertility. Aliabadi explains retrograde menstruation, immune dysfunction, and deep infiltrating disease, emphasizing that inflammation and scarring damage tubes, eggs, and implantation.
- •The leading theory is retrograde menstruation: menstrual cells flow backward through tubes into the pelvis.
- •In normal immunity, these cells are cleared; in susceptible women, immune dysfunction promotes their survival, vascularization, and local estrogen production.
- •Lesions develop their own blood supply and nerve fibers, producing severe chronic pain and central sensitization.
- •Endometriosis inflames the pelvis, scars tubes, destroys eggs/ovaries (endometriomas), and creates a hostile environment for sperm, eggs, and embryos.
- •Women with endometriosis face increased risks of blocked tubes, poor egg quality, ectopic pregnancies, and miscarriages; many also have adenomyosis within the uterine wall.
- 3:50:00 – 4:15:00
Surgery, Stromal Endometriosis, and Why Many Laps ‘Find Nothing’
They examine laparoscopic treatment and why so many women are told there is “no endometriosis” after surgery. Aliabadi criticizes limited training and rushed procedures that miss subtle stromal disease, sending desperate patients home without answers.
- •Gold standard care is laparoscopic excision (cutting out lesions), not just burning them.
- •Only ~1% of gynecologists are trained in advanced laparoscopic endometriosis surgery.
- •Typical “glandular” lesions look dark or blood-filled; many surgeons look only for these obvious spots.
- •Stromal endometriosis consists of fine fibrous bands with nerve fibers and often drives the worst pain and bloating; it’s easily missed unless you systematically scan the pelvis.
- •Many women wake from surgery told they don’t have endometriosis when in fact surgeons simply didn’t recognize or excise the disease.
- •Post-excision hormonal suppression (progestin IUD, plus sometimes GnRH antagonist) is critical to prevent rapid recurrence.
- 4:15:00 – 4:36:00
Medical Management of Endometriosis and Impact of Pregnancy
Aliabadi outlines non-surgical management, emphasizing that continuous progesterone-based suppression can be highly effective. She explains how pregnancy temporarily quiets disease and why hormone choices after birth and in menopause must be tailored in women with endometriosis.
- •Endometriotic lesions grow with estrogen and are slowed by progesterone; suppression is a mainstay of care.
- •Progesterone-only birth control pills or progestin IUDs (Kyleena/Mirena) can powerfully suppress endo symptoms and progression, especially in younger women.
- •GnRH antagonists (e.g., Orilissa, Myfembree) reduce estrogen and pain but can cause menopausal side effects and bone loss, limiting use to ~2 years.
- •Pregnancy typically suppresses endometriosis symptoms; Aliabadi inserts a progestin IUD shortly postpartum to prevent flares when cycles resume.
- •In menopause, unopposed estrogen HRT can reactivate endometriosis; endo patients should receive combined estrogen–progesterone, even without a uterus.
- 4:36:00 – 5:10:00
Redefining the Well Woman Exam and Access Problems
They zoom out to critique the standard well-woman exam and structural issues in women’s health care. Aliabadi argues that 50% of US counties lack an OB-GYN, ultrasound is rarely routine, and current checkups do little more than Pap smears and basic breast exams.
- •Current ‘well-woman’ visits often consist of a Pap smear, brief breast exam, optional STD testing, and a mammogram order after 40.
- •Pelvic ultrasound is rarely done despite being fast and crucial for detecting fibroids, ovarian cysts, septate uterus, and PCOS morphology.
- •Aliabadi believes OB and GYN training should be separated: one track for delivering babies, another for high-skill gynecologic medicine and surgery.
- •Time pressure (10-minute visits), burnout, and lack of training all contribute to misdiagnosis and dismissal.
- •She envisions AI and telemedicine as tools that could one day triage women and recognize patterns that rushed clinicians miss.
- 5:10:00 – 5:41:00
Fertility Buckets: A Practical Self-Checklist
Aliabadi offers a simple, powerful framework for any woman to self-audit infertility causes. She divides evaluation into discrete ‘buckets’ and shows how patients can walk into their doctor’s office already knowing what needs to be checked.
- •Bucket 1 – Female factor: hormones, AMH, thyroid, prolactin, STIs.
- •Bucket 2 – Male factor: semen analysis, lifestyle (e.g., daily cannabis), prior fertility issues.
- •Bucket 3 – Anatomy: pelvic ultrasound to assess fibroids, uterine septum, ovarian cysts; confirm tubal patency when indicated.
- •Bucket 4 – PCOS: evaluate irregular cycles, androgenic signs, AMH, and ovarian morphology.
- •Bucket 5 – Endometriosis: scrutinize period pain, sex pain, GI/bladder symptoms, regardless of imaging.
- •Bucket 6 – Autoimmune: lupus, antiphospholipid syndrome, thyroid autoimmunity, especially in recurrent miscarriage or endometriosis.
- •Patients can and should ask for specific labs and imaging associated with each bucket.
- 5:41:00 – 6:28:00
Breast Cancer Risk, Tyrer–Cuzick, and Aliabadi’s Own Cancer Story
They shift to breast cancer prevention. Aliabadi insists every woman should know her lifetime risk using Tyrer–Cuzick and adjust imaging accordingly. She recounts how this calculation, not family history, saved her own life when she pushed for prophylactic mastectomy and was found to have occult cancer.
- •Average lifetime breast cancer risk is ~12.5%, but family history, biopsies with atypia, dense breasts, childbearing patterns, and genetics can raise this significantly.
- •Risk categories: <15% low, 15–20% intermediate, ≥20% high; ≥20% warrants earlier and more intensive imaging (often starting ~30).
- •Tyrer–Cuzick risk can be calculated free on SheMD or via labs like Myriad, which also refine risk by adding polygenic markers.
- •In very high-risk women (≥35%), options include alternating mammogram and MRI every 6 months, chemoprevention with tamoxifen, or prophylactic mastectomy.
- •Aliabadi herself had no family history, but post-biopsy Tyrer–Cuzick was 37%; she was called paranoid for requesting mastectomy until a surgeon consented. Pathology then found a hidden breast cancer.
- •She states she has never lost a patient under her care to cancer, largely due to aggressive risk assessment and early detection.
- 6:28:00 – 6:56:00
Perimenopause, Menopause, and PMDD
Aliabadi outlines the storm of symptoms many women face in perimenopause—mood changes, sleep disruption, weight gain, joint pain, hair thinning—and how often this is missed. She also defines PMDD and offers a simple, evidence-based pulse SSRI approach that can be life-changing.
- •Perimenopause can start 7–10 years before menopause (often late 30s/early 40s), with hot flashes, night sweats, mood swings, weight gain, joint pain, vaginal dryness, and hair loss.
- •Most women are not diagnosed with perimenopause; they are simply told they are stressed or aging.
- •Menopause, PCOS, and endometriosis histories all influence HRT choices; endo patients must receive progesterone with estrogen.
- •PMDD is a severe form of PMS driven by brain sensitivity to normal hormonal changes: for ~10–14 days pre-period, women can become deeply depressed, irritable, and even suicidal.
- •PMDD is highly treatable: pulse-dose SSRIs such as fluoxetine 20 mg or sertraline 25 mg starting after ovulation and stopping at menses can markedly improve symptoms.
- •Perimenopausal PMDD-like patterns may respond well to a combination of HRT and targeted SSRIs.
- 6:56:00
Closing: A Call to Self-Advocacy and Systemic Change
The conversation concludes with Aliabadi’s broader vision: empowered women, restructured training for OB vs GYN, and truly comprehensive well-woman care. She reiterates that women’s pain is real, urges listeners to share this knowledge widely, and describes her dream of addressing the whole country about women’s health.
- •Aliabadi wants OB and GYN residency separated to allow deep expertise in each and better patient care.
- •Her ideal well-woman exam includes: full hormone panel, AMH, pelvic ultrasound, fertility assessment, PCOS/endo screening, lipid profile, ApoB, Lp(a), ApoE where relevant, autoimmune screen if indicated, and individualized breast cancer risk calculation.
- •She repeatedly emphasizes: women are not crazy; symptoms are real; dismissal is systemic, not personal failure.
- •Tools like Ovii (PCOS risk + supplements) and SheMD (education + Tyrer–Cuzick calculator) are designed to democratize access to information.
- •She urges men to learn this for daughters, partners, and sisters, and women to advocate forcefully for testing and imaging.
- •Huberman commits to amplifying her message and notes that this kind of public education can change both individual lives and medical culture over time.
